FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108202477> ?p ?o ?g. }

• W2108202477 endingPage "276" @default.
• W2108202477 startingPage "269" @default.
• W2108202477 abstract "Background: The aim of this study was to report the outcome of pure membranous lupus nephropathy treated with prednisone and azathioprine (AZA). Methods: Consecutive patients with pure membranous lupus glomerulonephritis (World Health Organization [WHO] Va and Vb) from 4 regional hospitals were recruited for an open-label treatment trial consisting of prednisone and AZA. Remission status was evaluated at 12 months. Maintenance treatment with low-dose prednisone and AZA was continued indefinitely for those who achieved remission. Factors predictive of initial renal remission and subsequent relapse were studied by statistical analyses. Results: Thirty-eight patients (31 women and 7 men) were studied. The mean age was 35.0 ± 9.2 years, and the duration of systemic lupus erythematosus was 48.5 ± 59 months. Seventeen (45%) patients had WHO class Va lupus nephritis, whereas 21 (55%) had class Vb disease. Two patients withdrew from the protocol because of idiosyncratic reactions to AZA. At 12 months, 24 (67%) patients achieved complete remission (CR), 8 (22%) achieved partial remission (PR), and 4 (11%) were treatment resistant. Patients who achieved CR or PR were maintained on low-dose prednisone and AZA. Over a mean follow-up period of 90.4 ± 59 months, 6 (19%) patients had relapse of nephritis (proteinuric flare in 4 and nephritic flare in 2). The cumulative risk of renal relapse was 12% at 36 months and 16% at 60 months. No particular clinical variables were found to predict renal remission or relapses. Over a mean follow-up of 90 months, 13% of patients had decline of creatinine clearance by 20%, but none had doubling of serum creatinine. Renal outcome was not significantly worse in patients presenting with nephrotic syndrome. Treatment generally was well tolerated. Conclusion: A combination of prednisone and AZA is reasonably effective for the initial treatment of pure membranous lupus nephritis. Severe adverse effects are uncommon. The additional efficacy of AZA in comparison with prednisone alone has to be confirmed with randomized, controlled trials." @default.
• W2108202477 created "2016-06-24" @default.
• W2108202477 creator A5003474969 @default.
• W2108202477 creator A5004488408 @default.
• W2108202477 creator A5033947419 @default.
• W2108202477 creator A5046621449 @default.
• W2108202477 creator A5047936070 @default.
• W2108202477 creator A5052148741 @default.
• W2108202477 creator A5090250944 @default.
• W2108202477 date "2004-02-01" @default.
• W2108202477 modified "2023-10-16" @default.
• W2108202477 title "Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial" @default.
• W2108202477 cites W1974878444 @default.
• W2108202477 cites W1978416104 @default.
• W2108202477 cites W1984716979 @default.
• W2108202477 cites W2010913974 @default.
• W2108202477 cites W2023960709 @default.
• W2108202477 cites W2025724624 @default.
• W2108202477 cites W2047722521 @default.
• W2108202477 cites W2048350130 @default.
• W2108202477 cites W2055268504 @default.
• W2108202477 cites W2069648600 @default.
• W2108202477 cites W2069834527 @default.
• W2108202477 cites W2074788260 @default.
• W2108202477 cites W2099342785 @default.
• W2108202477 cites W2145552180 @default.
• W2108202477 cites W2146203649 @default.
• W2108202477 cites W2148546748 @default.
• W2108202477 doi "https://doi.org/10.1053/j.ajkd.2003.10.029" @default.
• W2108202477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14750092" @default.
• W2108202477 hasPublicationYear "2004" @default.
• W2108202477 type Work @default.
• W2108202477 sameAs 2108202477 @default.
• W2108202477 citedByCount "77" @default.
• W2108202477 countsByYear W21082024772012 @default.
• W2108202477 countsByYear W21082024772013 @default.
• W2108202477 countsByYear W21082024772014 @default.
• W2108202477 countsByYear W21082024772015 @default.
• W2108202477 countsByYear W21082024772016 @default.
• W2108202477 countsByYear W21082024772017 @default.
• W2108202477 countsByYear W21082024772019 @default.
• W2108202477 countsByYear W21082024772020 @default.
• W2108202477 countsByYear W21082024772021 @default.
• W2108202477 countsByYear W21082024772022 @default.
• W2108202477 countsByYear W21082024772023 @default.
• W2108202477 crossrefType "journal-article" @default.
• W2108202477 hasAuthorship W2108202477A5003474969 @default.
• W2108202477 hasAuthorship W2108202477A5004488408 @default.
• W2108202477 hasAuthorship W2108202477A5033947419 @default.
• W2108202477 hasAuthorship W2108202477A5046621449 @default.
• W2108202477 hasAuthorship W2108202477A5047936070 @default.
• W2108202477 hasAuthorship W2108202477A5052148741 @default.
• W2108202477 hasAuthorship W2108202477A5090250944 @default.
• W2108202477 hasConcept C126322002 @default.
• W2108202477 hasConcept C134018914 @default.
• W2108202477 hasConcept C141071460 @default.
• W2108202477 hasConcept C2775946357 @default.
• W2108202477 hasConcept C2776760755 @default.
• W2108202477 hasConcept C2776912625 @default.
• W2108202477 hasConcept C2778720950 @default.
• W2108202477 hasConcept C2779134260 @default.
• W2108202477 hasConcept C2779147130 @default.
• W2108202477 hasConcept C2779912601 @default.
• W2108202477 hasConcept C2780091579 @default.
• W2108202477 hasConcept C2780368995 @default.
• W2108202477 hasConcept C2781184683 @default.
• W2108202477 hasConcept C555293320 @default.
• W2108202477 hasConcept C71924100 @default.
• W2108202477 hasConcept C90924648 @default.
• W2108202477 hasConceptScore W2108202477C126322002 @default.
• W2108202477 hasConceptScore W2108202477C134018914 @default.
• W2108202477 hasConceptScore W2108202477C141071460 @default.
• W2108202477 hasConceptScore W2108202477C2775946357 @default.
• W2108202477 hasConceptScore W2108202477C2776760755 @default.
• W2108202477 hasConceptScore W2108202477C2776912625 @default.
• W2108202477 hasConceptScore W2108202477C2778720950 @default.
• W2108202477 hasConceptScore W2108202477C2779134260 @default.
• W2108202477 hasConceptScore W2108202477C2779147130 @default.
• W2108202477 hasConceptScore W2108202477C2779912601 @default.
• W2108202477 hasConceptScore W2108202477C2780091579 @default.
• W2108202477 hasConceptScore W2108202477C2780368995 @default.
• W2108202477 hasConceptScore W2108202477C2781184683 @default.
• W2108202477 hasConceptScore W2108202477C555293320 @default.
• W2108202477 hasConceptScore W2108202477C71924100 @default.
• W2108202477 hasConceptScore W2108202477C90924648 @default.
• W2108202477 hasIssue "2" @default.
• W2108202477 hasLocation W21082024771 @default.
• W2108202477 hasLocation W21082024772 @default.
• W2108202477 hasOpenAccess W2108202477 @default.
• W2108202477 hasPrimaryLocation W21082024771 @default.
• W2108202477 hasRelatedWork W1480949964 @default.
• W2108202477 hasRelatedWork W1964664820 @default.
• W2108202477 hasRelatedWork W1992426553 @default.
• W2108202477 hasRelatedWork W2031799718 @default.
• W2108202477 hasRelatedWork W2044770659 @default.
• W2108202477 hasRelatedWork W2108202477 @default.
• W2108202477 hasRelatedWork W2370610172 @default.
• W2108202477 hasRelatedWork W2403288138 @default.

• next